IFPMA - Innovating to improve health worldwide

Latest news

Statement 2 February 2026

158th session of the WHO Executive Board (EB158): Priorities for financing noncommunicable diseases to achieve universal health coverage

On 2 February 2026, PATH delivered a joint constituency statement on Agenda itea 6: Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases at the 158th session of the WHO Executive Board. Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the...

Report 12 December 2025

The innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines

IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.

Closeup shot of two unrecognizable people holding hands in comfort

Expert insights 12 December 2025

A new dawn in global health: UHC as the path toward national health stewardship

The UHC High‑Level Forum in Tokyo marked an unmistakable turning point. It signaled a shift from dialogue to pragmatic action, with health and finance ministries jointly designing country‑owned, fiscally grounded UHC strategies to move beyond fragmented, crisis‑driven responses toward resilient, durable health systems that can make Universal Health Coverage (UHC) a reality. UHC means ensuring...

Position paper 11 December 2025

The role of assessment reports in enabling regulatory reliance - perspectives from the pharmaceutical industry

Reliance in decision-making offers a pathway for national regulatory authorities (NRAs) to consider evaluations conducted by other NRAs while maintaining accountability for their decisions. By avoiding duplicative reviews and optimizing resource allocation, the use of regulatory reliance can lead to faster patient access to safe, effective, and high-quality medical products in a timely manner. A...

Position paper 11 December 2025

Best practices for unilateral reliance for initial marketing authorization and post-approval changes

Regulatory reliance has emerged as a key strategy for strengthening regulatory systems by optimizing resources, reducing duplication, and accelerating access to high-quality medicines. By leveraging the expertise and prior decisions of trusted national regulatory authorities (NRAs), reliance allows NRAs to focus their efforts on critical public health priorities while maintaining sovereignty over final regulatory decisions....

Statement

158th session of the WHO Executive Board (EB158): Priorities for financing noncommunicable diseases to achieve universal health coverage

Report

The innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines

Expert insights

A new dawn in global health: UHC as the path toward national health stewardship

Position paper

The role of assessment reports in enabling regulatory reliance - perspectives from the pharmaceutical industry

Position paper

Best practices for unilateral reliance for initial marketing authorization and post-approval changes

Initiatives

See all

#VaccinesForLife

Investing in adult vaccination programmes can help protect lives, our healthcare systems, and our economies. Read the new report by the Office of Health Economics to discover more.

#AlwaysInnovating

#AlwaysInnovating lifts the curtain on the innovation journey, revealing the knowledge, skills, collaboration, and perseverance needed to turn an idea into a medicine or vaccine that brings hope to people everywhere.

Global Health Progress

Explore how the innovative pharmaceutical industry is collaborating across global health actors to support the Sustainable Development Goals in low- and middle-income countries.

Visit microsite

A female lab technician looking through a microscope

Collaborating for global health progress

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations.

About us

Areas of work

See all

Our members

Representing over 90 of the most forward-looking companies and associations in the world.

See all

Innovating to improve health worldwide

Latest news

158th session of the WHO Executive Board (EB158): Priorities for financing noncommunicable diseases to achieve universal health coverage

The innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines

A new dawn in global health: UHC as the path toward national health stewardship

The role of assessment reports in enabling regulatory reliance - perspectives from the pharmaceutical industry

Best practices for unilateral reliance for initial marketing authorization and post-approval changes

Initiatives

#VaccinesForLife

#AlwaysInnovating

Global Health Progress

Collaborating for global health progress

Areas of work

Fostering a thriving health innovation ecosystem

Advancing sustainable health systems

Improving health security and pandemic preparedness

Strengthening regulatory systems

Upholding ethics and business integrity

Supporting Africa’s health ecosystem

Our members

Share on Mastodon